Abbott Statement on
Agreement With Brazilian Government for
SAO PAULO, Brazil, July 11
/PRNewswire-FirstCall/ -- Abbott
(NYSE: ABT) announced that it achieved its goals in
agreement with the government of Brazil regarding
(lopinavir/ritonavir), the leading protease inhibitor.
accomplishes Abbott's objectives of helping Brazil
access to Kaletra while preserving the company's
property rights, which Abbott was not willing to
Most importantly, the agreement allows the Brazilian
expand the number of patients treated with Kaletra
the government's annual cost for Kaletra. The agreement
specify a per-capsule price. Instead, the price will be
upon the number of patients taking medication; it will
not be at the
low price quoted for local and generic manufacturers.
terms were not disclosed.
It is strong intellectual property protection that has
discovery and development of the many HIV treatments
patients today, and also ensures future advances to
address a virus
that continues to mutate and elude a cure. Abbott is
protecting its intellectual property so that innovation
for the benefit of patients around the world.
Upon the expiration of the patent in 2015, Brazil will
be able to
locally manufacture Kaletra for HIV/AIDS patients in
following Abbott's transfer of technology.
is always used in combination with
other anti-HIV medicines to treat people with human
virus (HIV) infection. KALETRA should not be taken by
have had an allergic reaction to KALETRA or any of its
including lopinavir or ritonavir.
Taking certain medications with KALETRA could create the
for serious side effects that could be life threatening.
should not be taken with astemizole, cisapride,
ergonovine, ergotamine, methylergonovine, midazolam,
terfenadine or triazolam.
In addition, KALETRA should not be taken with
rifampin, simvastatin, or products containing St. John's
(Hypericum perforatum). Particular caution should be
used when taking
KALETRA with sildenafil, tadalafil, or vardenafil.
your local prescribing information for country specific
recommendations. Discuss all medicines, including those
prescription and herbal preparations you are taking or
plan to take,
with your doctor or pharmacist.
Pancreatitis and liver problems, which can be fatal,
reported. Patients should tell their doctor if they have
disease such as hepatitis. In patients taking protease
increased bleeding (in patients with hemophilia) and
blood sugar have occurred. Changes in body fat have been
seen in some
patients receiving antiretroviral therapy. Some patients
KALETRA have had large increases in triglycerides and
Varying degrees of cross-resistance among protease
In KALETRA clinical trials, the most commonly reported
of moderate-to-severe intensity were abdominal pain,
movements, diarrhea, feeling weak or tired, headache,
vomiting. Children taking KALETRA may sometimes get a
This is not a complete list of reported side effects.
solution contains alcohol.
KALETRA does not cure HIV infection or AIDS and does not
risk of passing HIV to others. For more information,
prescribing information, please visit http://www.kaletra.com
Abbott is a global, broad-based health care company
devoted to the
discovery, development, manufacture and marketing of
and medical products, including nutritionals, devices
diagnostics. The company employs more than 60,000 people
its products in more than 130 countries.
Abbott's news releases and other information are
available on the
company's Web site at http://www.abbott.com .
FONTE Abbott Laboratories
CONTATO: U.S. Media, Melissa Brotz, +1-847-935-3456, or
International Media, Brian Kyhos, +1-847-936-7988, both
Web site: http://www.abbott.com
FONTE: PR NEWSWIRE LATIN AMERICA
CORAL GABLES - MIAMI-US
CONTATOS: USA-MARY D'LEON
PALAVRA-CHAVE/RAMO DE ATIVIDADE: INDÚSTRIA FARMACÊUTICA
PALAVRA-CHAVE/EMPRESA: ABBOTT LABORATORIES
O texto acima,
distribuído pela PR Newswire Brasil, é de inteira
responsabilidade de seu cliente. A utilização deste
implica em custo.